Medifast, Inc. (MED) Cash Flow Statement

The ratio is not meaningful in quarters where net income is near zero or negative, so the 2024Q3 and 2025Q3 readings reflect small denominators rather than true conversion strength. The more informative pattern is that operating cash flow was positive in only six of ten quarters and turned sharply negative in 2024Q4 and 2025Q4 despite the latter carrying a large $18.1M net loss. Investors should monitor whether working capital swings, rather than earnings quality, are driving these reversals.

Free cash flow has been driven largely by working capital timing rather than a stable operating base, as seen in the 2025Q3 swing to a $10.8M inflow followed by a $6.6M outflow one quarter later. Against a revenue base that fell by more than half over the period, the business appears to be generating less absolute cash per dollar of sales in its most recent quarters. This warrants further investigation into whether the 2026Q3 rebound to a 4.0 percent margin is sustainable.

When working capital movements are of comparable size to operating cash flow itself, the underlying cash profile is effectively masked by timing effects. The 2025Q2 outflow of $10.8M against a net income figure of only $2.5M suggests that receivables, inventory, or payables adjustments are absorbing cash that earnings do not reflect. Investors should monitor whether these movements reverse or indicate a structural shift in the company's working capital cycle.

Capital spending of roughly $0.4M to $2.3M per quarter sits below D&A in most periods, which may suggest the company is not replacing depreciating assets at the pace of their consumption. Because the data does not separate maintenance from growth capex, the true reinvestment requirement cannot be determined from these figures alone. The low intensity is consistent with a shrinking manufacturing and distribution footprint rather than a deliberate efficiency gain.

The cumulative figures suggest the cash generation problem is not simply a matter of depressed earnings but of recurring gaps between accrual income and cash receipts in both directions. Net losses of $17.5M and $18.1M in the two most recent Q3 and Q4 periods were accompanied by very different cash outcomes, reinforcing that the earnings line is an unreliable anchor. This divergence warrants caution in valuing the business on earnings-based metrics alone.